Cumulative Covid-19 vaccine doses administered in India exceed 528.9 mn

The cumulative Covid-19 vaccine doses administered in the country has exceeded 52.89 crore, the Union health ministry said on Thursday.

vaccine
Press Trust of India New Delhi
2 min read Last Updated : Aug 12 2021 | 11:15 PM IST

The cumulative COVID-19 vaccine doses administered in the country has exceeded 52.89 crore, the Union health ministry said on Thursday.

More than 50 lakh (50,77,491) doses were administered on Thursday, according to 7 pm provisional report.

The ministry said 27,83,649 vaccine doses were administered as first dose and 4,85,193 vaccine doses given as second dose, in the age group 18-44 years, on Thursday.

Cumulatively, 18,76,63,555 people in the age group 18-44 years across states/UTs have received their first dose and 1,39,23,085 have received their second dose since the start of phase-3 of the nationwide vaccination drive, it said.

Five states--Madhya Pradesh, Gujarat, Rajasthan, Maharashtra and Uttar Pradesh--have administered more than 1 crore cumulative doses of COVID-19 vaccine in the age group 18-44 years.

Also, Andhra Pradesh, Assam, Chhattisgarh, Delhi, Haryana, Jharkhand, Kerala, Telangana, Himachal Pradesh, Odisha, Punjab, Uttarakhand and West Bengal have vaccinated more than 10 lakh beneficiaries in the age group 18-44 years for the first dose of COVID vaccine, the ministry noted.

As on 209th day of the vaccination drive on Thursday, 50,77,491 vaccine doses were given.

The ministry said 39,49,956 beneficiaries were vaccinated for the first dose and 11,27,535 beneficiaries received second dose of vaccine according to the provisional report till 7 pm.

Final reports would be completed for the day by late night, it said.

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from the novel continues to be regularly reviewed and monitored at the highest level, the ministry said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineHealth Ministryclinical trials

First Published: Aug 12 2021 | 11:15 PM IST

Next Story